Clearside Biomedical, Inc.
900 North Point Parkway, Suite 200
Alpharetta
Georgia
30005
United States
Tel: 678-270-3631
Fax: 678-270-4033
Website: http://www.clearsidebio.com/
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a late-stage clinical ophthalmic biopharmaceutical company that envisions a world without blindness. Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and nonclinical product candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This offers potentially meaningful treatment benefit to patients suffering from sight threatening diseases like uveitis, retinal vein occlusion, diabetic macular edema and wet age-related macular degeneration. To learn more about how Clearside is changing ophthalmology, please visit us at www.clearsidebio.com.
Stock Symbol: CLSD
Stock Exchange: NASDAQ
179 articles about Clearside Biomedical, Inc.
-
Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients
11/9/2022
Clearside Biomedical, Inc. announced today positive results from its OASIS Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector® in neovascular age-related macular degeneration (wet AMD) patients.
-
Clearside Biomedical to Report OASIS Phase 1/2a Clinical Trial Results and Host Conference Call on Wednesday, November 9, 2022 in Conjunction with Third Quarter 2022 Financial Results
11/8/2022
Clearside Biomedical, Inc. announced that the Company will host a conference call on Wednesday, November 9, 2022 at 8:30 a.m. Eastern Time to report results from its OASIS Phase 1/2a clinical trial of CLS-AX in neovascular age-related macular degeneration patients.
-
Clearside Biomedical to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, November 9, 2022
11/2/2022
Clearside Biomedical, Inc., a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space, announced that its third quarter 2022 financial results will be reported on Wednesday, November 9, 2022 before the open of the financial markets.
-
Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical’s Proprietary Suprachoroidal Space Platform
10/4/2022
Clearside Biomedical, Inc. announced today that clinical data from multiple internal and partnered programs were presented at the recent 2022 Annual Meeting of the American Academy of Ophthalmology (AAO), the world's largest association of eye physicians and surgeons.
-
Clearside Biomedical to Present Corporate Overview and Upcoming Catalysts at Eyecelerator at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting
9/27/2022
Clearside Biomedical, Inc. announced that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will present a corporate overview at the Eyecelerator conference on September 29, 2022, as part of the Annual Meeting of the American Academy of Ophthalmology, the world's largest association of eye physicians and surgeons.
-
Clearside Biomedical to Present at the Ophthalmology Futures Retina Forum 2022
8/25/2022
Clearside Biomedical, Inc. announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer will present a company overview and participate in an industry panel virtually during the Ophthalmology Futures Retina Forum 2022 on August 31, 2022.
-
Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million- Transaction Supports Progression of CLS-AX Clinical Program -
8/8/2022
Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today it has entered into a Royalty Interest Purchase and Sale Agreement (the agreement) with HealthCare Royalty Partners (HealthCare Royalty).
-
Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients
7/26/2022
Clearside Biomedical, Inc. announced today completion of dosing in Cohorts 3 and 4 of OASIS, its Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with neovascular age-related macular degeneration (wet AMD).
-
Clearside Biomedical Expands Leadership Team with Appointment of Susan Coultas, Ph.D., as Chief Clinical Officer
6/14/2022
Clearside Biomedical, Inc. today announced the appointment of Susan L. Coultas, Ph.D., as Chief Clinical Officer.
-
Clearside Biomedical to Participate in the JMP Securities Life Sciences Conference
6/8/2022
Clearside Biomedical, Inc. announced that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will participate in a Fireside Chat at the JMP Securities Life Sciences Conference on Wednesday, June 15, 2022, at 9:30 a.m. Eastern Time, in New York, NY.
-
Clearside Biomedical Announces First Quarter 2022 Financial Results and Provides Corporate Update
5/11/2022
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
-
Clearside Biomedical Poster Presentation at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Delivery Technology
5/5/2022
Clearside Biomedical, Inc. announced that several poster presentations were delivered on Clearside’s proprietary suprachoroidal delivery platform, XIPERE®, and gene therapy delivery utilizing Clearside’s SCS Microinjector® at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting.
-
Clearside Biomedical to Report First Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, May 11, 2022
4/29/2022
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2022 financial results will be reported on Wednesday, May 11, 2022 after the close of the financial markets
-
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
3/28/2022
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), and Clearside Biomedical, Inc. (Nasdaq: CLSD) ("Clearside"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today announced the U.S. commercial launch of XIPERE®.
-
Clearside Biomedical Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
3/10/2022
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.
-
Clearside Biomedical Appoints Benjamin R. Yerxa, Ph.D. to its Board of Directors
3/3/2022
Clearside Biomedical, Inc., a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space, announced that Benjamin R. Yerxa, Ph.D., has been appointed to the Company's Board of Directors, effective March 2, 2022.
-
Clearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2022
3/1/2022
Clearside Biomedical, Inc. announced that it will participate in the following investor conferences in March 2022.
-
Clearside Biomedical to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Thursday, March 10, 2022
2/25/2022
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2021 financial results will be reported on Thursday, March 10, 2022 after the close of the financial markets.
-
Clearside Biomedical’s Suprachoroidal Injection Platform Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conference
2/14/2022
Clearside Biomedical, Inc. announced that multiple oral presentations on Clearside’s SCS injection platform featuring the SCS Microinjector® were given at the Bascom Palmer Eye Institute’s Angiogenesis, Exudation, and Degeneration 2002 Virtual Event held February 11-12, 2022.
-
Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conference on February 12, 2022
2/2/2022
Clearside Biomedical, Inc., a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space, announced that Clearside’s SCS injection platform featuring the SCS Microinjector® will be featured in multiple oral presentations at the Bascom Palmer Eye Institute’s Angiogenesis, Exudation, and Degeneration 2002 Virtual Event to be held February 11-12, 2022.